OBT at a glance

Pioneering an Innovative Approach for the Development of First-in-Class Cancer Therapies

Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Our proprietary, proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets.
This platform supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities. We continuously enhance our OGAP®-Verify database to accurately represent patient tumours and the tumour microenvironment. Our fully integrated discovery and development capabilities span from target identification to IND-enabling studies.
View our Pipeline

OBT’s mission is to become a key player in the ADC and T-cell engagers (TCE) field, with a reputation for innovation, scientific excellence, and commitment to improving patient outcomes and bringing much-needed therapies to patients worldwide

Our Team

Our success at Oxford BioTherapeutics is driven by a team that expertly combines scientific rigour with medical expertise

Christian Rohlff, PhD

Chief Executive Officer, Oxford

Harald Haeske, MD, MBA

Chief Medical Officer, Oxford

Benjamin Thomas, PhD

SVP Operations, Oxford

Martin Barnes, DPhil

SVP Bioinformatics and Information Systems, Oxford

Patrick Duxbury, BSc(Hons), CPE

General Counsel, Oxford

Andrew Dickinson, MSc

VP of Clinical Operations, Oxford

Stephanie Holmes, ACA

Senior Finance Director, Oxford

Bridget Biggar

Head of Human Resources, Oxford

Stephen Blance, PhD CPA EPA

Director of Intellectual Property, Oxford

Somdatta Basu

Director, Business Development and Target Discovery, Oxford

Belinda Cairns, PhD

Director of IHC Sciences, San Jose

Javier Morales, PhD

Director, Antibody Discovery, San Jose

Yu-Tzu Tai, PhD

Director ADC & Translational Research, San Jose

Matthew Metzger

Director, Alliance Management, San Jose

Madeline Tran

Associate Director of Protein Sciences, San Jose

Investors

Oxford BioTherapeutics is Supported by a Syndicate of Leading Specialist Investors

A major portion of the investment into our ADC, IO, CAR-T and bispecific pipeline comes from strategic alliances with leading companies in the oncology field.

Yu-Tzu Tai, PhD

Director ADC & Translational Research, San Jose

Dr. Tai joined Oxford Biotherapeutics in July 2022, bringing expertise in cancer and immune oncology research from novel target identification to translational investigations. Her preclinical work has led to FDA-approved cancer and immune therapies including small molecules (BTK, XPO1, IMiDs, Proteasome inhibitors) and biologics (CD38, SLAMF7, BCMA, APRIL, LAG3). She has authored over 210 scientific articles with an h-index of 100 on Google Scholar and spent 25 years at Dana-Farber Cancer Institute, holding patent publications. Dr. Tai is a long-term member of AACR and actively serves on the editorial board of the Clinical Cancer Research Journal. At Oxford Biotherapeutics, she oversees ADC programs and preclinical studies for ongoing OBT076 trials while supporting external partnerships, all aimed at developing innovative immunotherapies for patients. She earned her PhD in the environmental toxicology program focused on human oncology from the University of Wisconsin-Madison.